Drug Approval | September 16, 2025
Rona submits IND for GalNAc-conjugated siRNA targeting obesity
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Element5’s Agentic AI platform will be integrated with the HCHB EHR
The FDA is beginning rulemaking to close the “adequate provision” loophole
Cagrilintide represents a novel approach to obesity management
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Subscribe To Our Newsletter & Stay Updated
